- Home
- SRG vs CABA Comparison
SRG vs CABA Comparison
Compare SRG & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- CABA
- Stock Information
- Founded
- SRG 2014
- CABA 2017
- Country
- SRG United States
- CABA United States
- Employees
- SRG N/A
- CABA N/A
- Industry
- SRG Real Estate Investment Trusts
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRG Real Estate
- CABA Health Care
- Exchange
- SRG Nasdaq
- CABA Nasdaq
- Market Cap
- SRG 185.9M
- CABA 149.3M
- IPO Year
- SRG 2015
- CABA 2019
- Fundamental
- Price
- SRG $2.85
- CABA $1.65
- Analyst Decision
- SRG
- CABA Strong Buy
- Analyst Count
- SRG 0
- CABA 7
- Target Price
- SRG N/A
- CABA $14.29
- AVG Volume (30 Days)
- SRG 104.5K
- CABA 1.3M
- Earning Date
- SRG 08-22-2025
- CABA 08-07-2025
- Dividend Yield
- SRG N/A
- CABA N/A
- EPS Growth
- SRG N/A
- CABA N/A
- EPS
- SRG N/A
- CABA N/A
- Revenue
- SRG N/A
- CABA N/A
- Revenue This Year
- SRG N/A
- CABA N/A
- Revenue Next Year
- SRG N/A
- CABA N/A
- P/E Ratio
- SRG N/A
- CABA N/A
- Revenue Growth
- SRG N/A
- CABA N/A
- 52 Week Low
- SRG $2.43
- CABA $0.99
- 52 Week High
- SRG $4.85
- CABA $6.26
- Technical
- Relative Strength Index (RSI)
- SRG 35.98
- CABA 54.35
- Support Level
- SRG $2.81
- CABA $1.26
- Resistance Level
- SRG $2.95
- CABA $1.75
- Average True Range (ATR)
- SRG 0.12
- CABA 0.12
- MACD
- SRG -0.04
- CABA 0.02
- Stochastic Oscillator
- SRG 6.90
- CABA 79.59
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.